Lilly-funded analysis finds tirzepatide beat semaglutide on weight and metabolic markers
Comparing SURMOUNT-1 and STEP 1, researchers in Barcelona report tirzepatide 10 and 15 mg led to 5 to 6.5 kg more loss, plus gains in lean mass share.
Recap by typeshit. Full story at Bioengineer.org.